Founders Capital Management LLC lessened its stake in shares of Johnson & Johnson (NYSE: JNJ – Get Rating) by 1.5% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 26,680 shares of the company stock after selling 420 shares during the period. Johnson & Johnson comprises approximately 1.0% of Founders Capital Management LLC’s investment portfolio, making the stock its 24th biggest holding. Founders Capital Management LLC’s holdings in Johnson & Johnson were worth $ 4,564,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Steward Financial Group LLC acquired a new position in Johnson & Johnson during the fourth quarter valued at $ 34,000. Jackson Wealth Management LLC increased its stake in shares of Johnson & Johnson by 1.7% during the third quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company stock worth $ 40,000 after purchasing an additional 277 shares in the last quarter. Iron Horse Wealth Management LLC grew its stake in Johnson & Johnson by 29.9% during the 4th quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company stock valued at $ 45,000 after acquiring an additional 61 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its stake in Johnson & Johnson by 290.7% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company stock valued at $ 47,000 after acquiring an additional 218 shares in the last quarter. Finally, Gibson Wealth Advisors LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $ 49,000. 68.78% of the stock is owned by hedge funds and other institutional investors.
NYSE JNJ opened at $ 168.19 on Wednesday. The company has a 50 day simple moving average of $ 178.83 and a 200-day simple moving average of $ 172.64. Johnson & Johnson has a 52-week low of $ 155.72 and a 52-week high of $ 186.69. The firm has a market capitalization of $ 442.58 billion, a price-to-earnings ratio of 22.67, a price-to-earnings-growth ratio of 3.41 and a beta of 0.66. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14.
Johnson & Johnson (NYSE: JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, April 19th. The company reported $ 2.67 EPS for the quarter, beating the consensus estimate of $ 2.60 by $ 0.07. The company had revenue of $ 23.43 billion for the quarter, compared to the consensus estimate of $ 23.62 billion. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The company revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter last year, the company posted $ 2.59 earnings per share. On average, analysts predict that Johnson & Johnson will post 10.23 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th were paid a $ 1.13 dividend. The ex-dividend date was Monday, May 23rd. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $ 1.06. This represents a $ 4.52 dividend on an annualized basis and a dividend yield of 2.69%. Johnson & Johnson’s dividend payout ratio (DPR) is 60.92%.
JNJ has been the topic of a number of analyst reports. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $ 175.00 to $ 173.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 6th. Bank of America assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, March 2nd. They set a “neutral” rating on the stock. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. Citigroup lowered their target price on shares of Johnson & Johnson from $ 210.00 to $ 205.00 in a report on Tuesday, May 17th. Finally, The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $ 163.00 to $ 181.00 and gave the company a “neutral” rating in a research note on Tuesday, April 12th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Buy” and a consensus price target of $ 190.50.
In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $ 180.00, for a total value of $ 1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares in the company, valued at approximately $ 2,785,140. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider William Hait sold 29,699 shares of the company stock in a transaction that occurred on Thursday, April 21st. The stock was sold at an average price of $ 183.58, for a total value of $ 5,452,142.42. Following the sale, the insider now owns 80,236 shares in the company, valued at approximately $ 14,729,724.88. The disclosure for this sale can be found here. Over the last quarter, insiders sold 101,842 shares of company stock valued at $ 18,069,079. Corporate insiders own 0.35% of the company stock.
About Johnson & Johnson: (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.
See Also:
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE: JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.
.